• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.79% Nasdaq Up0.53%

    More On PXS.AX



    News & Info


    Analyst Coverage


    • Major Holders
    • Insider Transactions
    • Insider Roster


    Pharmaxis Ltd. (PXS.AX)

    0.26 Up 0.02(6.25%) 1:06AM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Pharmaxis Ltd.
    20 Rodborough Road
    Frenchs Forest, NSW 2086
    Australia - Map
    Phone: 61 2 9454 7200
    Fax: 61 2 9451 3622
    Website: http://www.pharmaxis.com.au

    Index Membership:N/A
    Industry:Drug Manufacturers - Major
    Full Time Employees:83

    Business Summary 

    Pharmaxis Ltd, a specialty pharmaceutical company, engages in the research, development, and commercialization of human healthcare products for the treatment and management of respiratory and other chronic diseases worldwide. The company’s lead product and product candidates are used for the diagnosis and treatment of chronic respiratory diseases, including asthma, cystic fibrosis, and chronic obstructive pulmonary disease (COPD), including bronchiectasis and chronic bronchitis, and other chronic and acute pulmonary conditions. It offers Aridol lung function test, which is designed to assist physicians in the assessment of asthma by identifying and measuring airway hyperresponsiveness; and Bronchitol, a drug designed to reduce the amount of mucus build-up in the lungs of patients suffering from chronic respiratory conditions. The company’s early product development pipeline includes orbital dry powder inhaler that delivers drug doses to the lungs; Lysyl Oxidase Like 2 (LOXL-2) inhibitors for the treatment of fibrosis; PXS64/25 targeting lung fibrosis; ASM8 targeting severe asthma; and PXS TPI1100 for the treatment candidate for COPD. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Pharmaxis Ltd.

    Key Executives 
    Mr. Gary Jonathan Phillips BPharm, MBA, 54
    Chief Exec. Officer, Director and Member of Disclosure Committee
    Mr. David Morris McGarvey BA, CA, CPA, 59
    Chief Financial Officer, Company Sec. and Member of Disclosure Committee
    Mr. Wolfgang Jarolimek ,
    Head of Drug Discovery
    Dr. Brett Charlton MBBS Ph.D., 59
    Medical Director and Member of Disclosure Committee
    Mr. Cameron David Billingsley BA, LLB (Hons.), 38
    Gen. Counsel
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in AUD.